The Global NASH/MASH Council (GNC) has published its 2026 Updated Global Consensus Recommendations for MASLD/MASH in Clinical Gastroenterology and Hepatology. Developed through a structured Delphi process involving 40 international experts, these recommendations provide a practical, evidence-based framework for identifying high-risk patients, assessing liver fibrosis using noninvasive tests (FIB-4, VCTE, and ELF), initiating newly approved therapies (resmetirom and semaglutide), and monitoring treatment response. The consensus emphasizes individualized, risk-based treatment, integration of lifestyle interventions, and standardized approaches to improve clinical decision-making and patient outcomes worldwide.
